08:11 AM EDT, 08/11/2025 (MT Newswires) -- Kamada ( KMDA ) said Monday that the US Food and Drug Administration has approved the supplement to its existing biologics license application for its Houston, Texas, plasma collection center after a recent on-site inspection.
The company said the 12,000-square foot facility, which can collect about 50,000 liters of plasma annually, is now cleared to begin commercial sales of normal source plasma.
Kamada ( KMDA ) said it also plans to seek European approval for the site.
Besides its Houston and Beaumont locations, the company said it has opened its third center in San Antonio, Texas. The Houston and San Antonio sites are each expected to generate annual revenue of $8 million to $10 million at full capacity, Kamada ( KMDA ) added.
Shares of Kamada ( KMDA ) were up more than 6% in recent premarket activity Monday.